Avid Bioservices Announces Appointment of Two Senior Directors of Business Development with Responsibility for North America,...
April 13 2020 - 8:05AM
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated
biologics contract development and manufacturing organization
(CDMO) working to improve patient lives by providing high quality
development and manufacturing services to biotechnology and
pharmaceutical companies, today announced the appointment of two
senior directors of business development with responsibility for
driving CDMO business growth within North America, Europe and
Asia. Jason C. Brady, Ph.D. will serve as senior director of
business development for the eastern region of North America, as
well as Europe. Sylvia Hinds has been named senior director
of business development for the western region of North America in
addition to the Asia Pacific region.
Dr. Brady is an accomplished sales professional
with an extensive track record of successfully securing new
manufacturing contracts with biopharmaceutical clients. He
most recently served as senior director of sales and business
development at Aji Bio-Pharma, a leading global provider of
biopharmaceutical contract development and manufacturing
services. During his five years in this position, he managed
the company’s expansion into the development and manufacturing of
antibody drug conjugates, as well as the onboarding of new clients
focused on fill/finish of complex biologics. Prior to Aji
Bio-Pharma, Dr. Brady spent eight years at Lonza, a global leader
in the manufacture of biologics. At Lonza he served in
various commercial positions of increasing responsibility with a
focus on securing manufacturing and service contracts for the
company’s global biologics manufacturing network, as well as
leading an expansion into new manufacturing technologies. In his
new role with Avid, Dr. Brady will be responsible for driving the
continued growth and expansion of the company’s CDMO business in
the eastern portion of North America and Europe.
Ms. Hinds possesses nearly 17 years of
experience in key business development roles in the CDMO and
contract research organization (CRO) industries, having established
specialized expertise in biologics, gene and cell therapy, and
sterile fill/finish services. In these roles, she has
demonstrated the proven ability to consistently develop and
penetrate new markets and exceed sales revenue targets. Ms.
Hinds most recently held the title of director, business
development, North America western region for oligonucleotide-based
gene therapy services at Nitto Denko Avecia. During her
career, she has also held positions of increasing responsibility
with Brammer Bio, Novasep, Cook Pharmica and Baxter, delivering
impressive results in the areas of new business generation and
revenue growth, among others. In her new role with Avid, Ms.
Hinds will be charged with expanding the company’s CDMO business
with both new and existing clients in the western portion of North
America and the Asia Pacific region.
“The additions of Jason and Sylvia, coupled with
our recent appointment of Tim Compton as chief commercial officer,
provide Avid with an experienced business development team with a
proven track record of success in the CDMO field. We have
already begun to see a noticeable uptick in customer engagement and
opportunities in the short time that Tim has been on board and
expect that the efforts of Sylvia and Jason will significantly
accelerate that trend,” said Rick Hancock, interim president
and chief executive officer of Avid. “We are pleased to
welcome Sylvia and Jason to the Avid team and look forward to the
important contributions that they will make in supporting our
efforts to drive meaningful business and revenue growth.”
About Avid
Bioservices, Inc.
Avid Bioservices is a dedicated contract
development and manufacturing organization (CDMO) focused on
development and CGMP manufacturing of biopharmaceutical products
derived from mammalian cell culture. The company provides a
comprehensive range of process development, high quality CGMP
clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With over 25 years
of experience producing monoclonal antibodies and recombinant
proteins in batch, fed-batch and perfusion modes, Avid's services
include CGMP clinical and commercial product manufacturing,
purification, bulk packaging, stability testing and regulatory
strategy, submission and support. The company also provides a
variety of process development activities, including cell line
development and optimization, cell culture and feed optimization,
analytical methods development and product
characterization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Sep 2023 to Sep 2024